Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms

Sponsor
Shirley Ryan AbilityLab (Other)
Overall Status
Recruiting
CT.gov ID
NCT04393558
Collaborator
(none)
100
1
32.4
3.1

Study Details

Study Description

Brief Summary

  1. Develop a wearable sensor package to gather data on COVID-19-like signs and symptoms such as elevated body temperature, respiratory parameters, heart rate ,cough and gait.

  2. Create algorithms to monitor and track changes to COVID19-like signs and symptoms for developing a better care and isolation strategies for COVID-19 pandemic.

Condition or Disease Intervention/Treatment Phase
  • Device: ADAM Sensor

Detailed Description

Aim 1:

Each enrolled participant will be asked to wear the sensor on a daily basis. Duration of the participation varies based on the symptom severity. With the currently available information, recovery times are ranging from 7 days to 56 days. The duration of the study participation can begin at the early detection to all the way until complete recovery or discharge. Participants may be asked to use the sensors anywhere from 7 days to 60 days. Duration of study will be based on the participant's self-reported symptoms or as appropriate determined by the PI. This will allow the research team to collect a comprehensive data set that can characterize both COVID-like and non-COVID-like signs and symptoms.

Aim 2:

Data collected from Aim#1 will aid in generating machine learning algorithms to characterize the signs and symptoms. Further algorithm development will be carried out to develop signs and symptoms progression and regression models for early warning or warning to prevent return to work of health-care staff or civilians

Wearable sensors are compact battery powered miniature electronic devices that are attached to a user's body to record physiological, biochemical and physical activity information. Different types of sensors can be used to monitor these digital biomarkers. Inertial measurement units (IMUs), including accelerometers, gyroscopes, magnetometers are typically used to measure physical activity, movement signatures. Miniature temperature, galvanic skin response (GSR), photoplethysmogram (PPG), oxygen saturation (SPO2) sensors are increasingly embedded in wearable devices for vital sign monitoring. Non-invasive monitoring is very ideal in the current pandemic situation. These sensors can be potentially deployed in large scale to monitor cases of suspected infection and patients recovering from COVID-19.

This project is planning to develop a sensor system that is capable of gathering data on COVID-19 like symptoms such as cough, body temperature, respiratory parameters. Machine algorithms will be developed to handle data analysis and derive useful clinical and monitor signs and symptoms in cases of suspected infection and individuals actively recovering from COVID-19 like symptoms

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms
Actual Study Start Date :
Apr 20, 2020
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
COVID-19

Individuals experiencing COVID-19 like symptoms.

Device: ADAM Sensor
ADAM sensor The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.

Healthy Controls

Individuals without any known significant health problems

Device: ADAM Sensor
ADAM sensor The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.

Outcome Measures

Primary Outcome Measures

  1. Body temperature [Minimum 7 days from day 1 of study enrollment up to 60 days]

    Body temperature : Periodic temperature readings over the day (every 15 minutes)

  2. Cough Frequency [Minimum 7 days from day 1 of study enrollment up to 60 days]

    Number of coughing episodes in an hour

  3. Respiratory frequency [Minimum 7 days from day 1 of study enrollment up to 60 days]

    Number of breaths per minute

  4. Heart Rate Instantaneous heart rate every 15 minutes. [Minimum 7 days from day 1 of study enrollment up to 60 days]

    Instantaneous heart rate every 15 minutes

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 95 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Ages between 18-95 years old

  • Currently experiencing any COVID-like signs and symptoms such as fever, cough, shortness of breath, trouble breathing, persistent pain or pressure in the chest, confusion or inability to arouse, bluish lips or face.

  • Individuals who are not experience any COVID like signs and symptoms (will be asked to be healthy control)

  • Able and willing to give written consent and comply with study procedures.

Exclusion Criteria:
  • Inability to understand instructions and follow a three step command.

  • The subject is pregnant, nursing or planning a pregnancy.

  • Inability to provide written consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Shirley Ryan AbilityLab Chicago Illinois United States 60611

Sponsors and Collaborators

  • Shirley Ryan AbilityLab

Investigators

  • Principal Investigator: Arun Jayaraman, PhD, Shirley Ryan AbilityLab

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Arun Jayaraman, PT, PhD, Director Max Nader Laboratory, Shirley Ryan AbilityLab
ClinicalTrials.gov Identifier:
NCT04393558
Other Study ID Numbers:
  • STU00212522
First Posted:
May 19, 2020
Last Update Posted:
Oct 4, 2021
Last Verified:
Oct 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Arun Jayaraman, PT, PhD, Director Max Nader Laboratory, Shirley Ryan AbilityLab
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 4, 2021